Marcin Dyba

Leidos (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.9kcitations80works4.32yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genomics, phytochemicals, and oxidative stress(14), Cancer, Hypoxia, and Metabolism(13), Nitric Oxide and Endothelin Effects(9), RNA and protein synthesis mechanisms(6), Metabolism, Diabetes, and Cancer(6)

Publications80 total

Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia

Molecular Cancer Therapeutics·2025

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction

13 cited

Science·2025· 13 cited

Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints

6 cited

Journal of Biological Chemistry·2025· 6 citedOpen Access

Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine

3 cited

Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access

NMR 1H, 13C, and 15N resonance assignments of the oncogenic Q61R variant of human NRAS in the active, GTP-bound conformation

Biomolecular NMR Assignments·2025Open Access

Abstract 3788: BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models

Cancer Research·2025

Supplementary Figure S6 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Table S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S3 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Table S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S4 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S5 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Material and Methods from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Data from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

33 cited

Cancer Discovery·2024· 33 citedOpen Access

Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding

10 cited

Cancer Research·2024· 10 cited

Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR

19 cited

Journal of Biological Chemistry·2024· 19 citedOpen Access

MALDI-TOF Mass Spectrometry-Based Assay for Measuring Covalent Target Engagement of KRAS G12C Inhibitors

2 cited

Methods in molecular biology·2024· 2 cited

page 1 of 4Next →

Frequent Co-authors

Fung‐Lung Chung(16), Henryk Kozłowski(13), Jishen Pan(8), Dwight V. Nissley(8), Andrew G. Stephen(7), Frank McCormick(7), Wojciech Bal(6), Deborah L. Berry(6), Małgorzata Jeżowska‐Bojczuk(6), Ying Fu(6), Yue Yang(6), Dana Rabara(6), Erik K. Larsen(6), Dominic Esposito(6), Felice C. Lightstone(6), Dhirendra K. Simanshu(6), Anna E. Maciag(5), Alok K. Sharma(5), Albert H. Chan(5), Pedro J. Beltran(5)